Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Haseeb, Abid; Solyman, Omar; Abushanab, Mokhtar Mohamed Ibrahim; Obaia, Ahmed S. Abo; Elhusseiny, Abdelrahman M.

doi:10.3390/vaccines10020342

Cited by 59 publications

(49 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both inactivated COVID-19 vaccines were absorbed with aluminum-based adjuvant and have been reported tolerable and immunogenic in healthy people with two doses administered 21 days apart [ 3 , 4 ]. Although effective and well-tolerated in most patients, COVID-19 vaccines can uncommonly cause various ocular adverse effects [ 5 , 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Chen

et al. 2022

Vaccines

View full text Add to dashboard Cite

Aims: To report potential vaccine-induced ocular adverse events following inactivated COVID-19 vaccination (Sinopharm and Sinovac). Methods: This case series took place at a tertiary referral center in the southeast of China (Xiamen Eye Center in Fujian Province) from February 2021 to July 2021. Patients who received the first dose of inactivated COVID-19 vaccine and developed vaccine-related ocular adverse events within 10 days were included. The diagnosis of vaccine-related ocular adverse events was guided by the World Health Organization causality assessment and the Naranjo criteria. Results: Ten eyes of seven patients (two male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30–55 years). The mean time of ocular adverse event manifestations was 4.9 days (range, 1–10 days). Three patients were diagnosed with Vogt–Koyanagi–Harada (VKH)-like uveitis, one with multifocal choroiditis, one with episcleritis, one with iritis, and one with acute idiopathic maculopathy. Two patients received the second dose of vaccine. One patient had exacerbation of VKH, and one patient had no symptoms. An aqueous humor analysis in three patients revealed elevated proinflammatory cytokines and negative virus copy. All the patients had transient ocular disturbance and responded well to steroids. No recurrence was noted during 6 months of follow-up. Conclusions: Potential ocular adverse events should be reported to increase the awareness of the health community for timely detection and proper treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Chen

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…Since the administration of COVID-19 vaccinations, numerous reports have discussed different adverse ocular effects following vaccination. In a recent study, Haseeb AA et al compiled retrospective clinical data of all published reports, within 1 year, of cases with various ocular manifestations following vaccination against COVID-19 [ 34 ]. The found a marginal predominance of the female gender (54.9%) among reported cases.…”

Section: Discussionmentioning

confidence: 99%

“…The found a marginal predominance of the female gender (54.9%) among reported cases. AZD1222 ChAdO× 1 nCoV-19, Covishield (Serum Institute of India vaccine, also marketed as (AstraZeneca, Cambridge, UK) was reported 20 (22.9%) times, second only to BNT162b2 mRNA SARS-CoV-2 (BioNTech/Pfizer, Mainz, Germany), which was reported 55 (63.2%) times [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Reactivation of juvenile idiopathic arthritis associated uveitis with posterior segment manifestations following anti-SARS-CoV-2 vaccination

Mahendradas

Mishra

Mangla

et al. 2022

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Background/purpose Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in the pediatric population and anterior uveitis is its commonest extra-articular manifestation. Typically the uveitis presents as chronic anterior uveitis and there is limited literature of the posterior segment manifestations of the disease. Similar to other vaccines, anti-SARS-CoV-2 vaccination that began as an urgent measure to control the spread of the SARS-CoV-2 pandemic has not been without adverse events. We are reporting a 19-year-old Asian Indian female who was diagnosed and treated for JIA associated anterior uveitis that was unilateral and was under anti-inflammatory control but showed worsening of uveitis with posterior segment inflammation in both eyes following anti-SARS-CoV-2 vaccination. Case report A 19-year-old Asian Indian female with a history of juvenile idiopathic arthritis on treatment with methotrexate, presented with right eye chronic anterior uveitis with peripheral subclinical retinal vasculitis and macular edema which was brought under control following administration of adalimumab. She was inflammation free for 6 months until she received anti-SARS-CoV-2 vaccination and developed new onset floaters in both eyes that were initially noted after the first dose and increased after the second dose. Clinical examination revealed presence of keratic precipitates and grade 1+ anterior chamber inflammation along with vitiritis in both eyes. Fundus fluorescein angiography revealed angiographically active retinal vasculitis without the presence of macular edema in both eyes. This was managed with a short course of topical difluprednate and continuation of systemic immunosuppressive therapy with adalimumab and methotrexate. Conclusion JIA associated uveitis results from an autoimmune process which can be controlled with timely immunosuppressive treatment. It is important to be aware of the potential risk of flare up of uveitis with posterior segment manifestations following anti- SARS-CoV-2 vaccination.

show abstract

“…In terms of ophthalmic reaction to COVID-19 vaccination, various manifestations including eyelid swelling, ptosis, superior ophthalmic vein thrombosis, acute graft rejection after keratoplasty, cranial nerve palsy, retinal vein occlusion, submacular hemorrhage, scleritis, uveitis, acute macular neuroretinopathy, optic neuritis, and paracentral acute middle maculopathy were found in several cases [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. The COVID-19 vaccines with reported ophthalmic reactions included the mRNA vaccine (BNT162b2, Pfizer, Brooklyn, NY, USA; mRNA-1273, Moderna, Cambridge, MA, USA), vector vaccine (Ad26COVS1, Janssen Johnson & Johnson, New Brunswick, NJ, USA; AZD1222, Oxford–AstraZeneca, Cambridge, UK), and whole virus (PiCoVacc, Sinovac Biotech, Beijing, China; BBIBP-CorV, Sinopharm, Beijing, China) [ 14 , 15 ]. However, the causal relationship and the mechanisms by which these conditions develop remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Vision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019

Choi

Seo

Choi

et al. 2022

JCM

View full text Add to dashboard Cite

A single-center retrospective observational case series was conducted. This case series enrolled patients who showed ophthalmic manifestations within one week after COVID-19 vaccination at Korea University Guro Hospital in Seoul, Korea, from May 2021 to January 2022. The medical records of patients who complained of ocular symptoms and showed ophthalmic adverse events within one week after COVID-19 vaccination were reviewed. Seventeen eyes from 16 patients with a mean age of 63.8 (range 33–83) years were included in the case series, and all symptoms developed within 1–7 days following inoculation. Retinal vein occlusion in nine eyes (52.9%), retinal artery occlusion in one eye (5.9%), newly developed anterior uveitis in one eye (5.9%), exacerbation of previously diagnosed panuveitis in two eyes (11.8%), and angle-closure attack with high intraocular pressure in four eyes (23.5%) were included. Twelve patients (75%) had been vaccinated with the AstraZeneca (AZD1222) and four (25%) with the Pfizer (BNT162b2) vaccines. Of these, 10 patients (62.5%) experienced ocular disease exacerbation after the first dose, 4 (25%) after the second dose, and 2 (12.5%) after the third dose (booster shot). Eleven patients (64.7%) underwent tests for hematological abnormalities, and three of them tested positive for anti-PF4 antibodies, but no abnormal findings were noted. A causal relationship between vaccination and the ocular manifestations could not be determined, which is a limitation of this study. However, clinicians should consider the effect of COVID-19 vaccination on ophthalmic disease. Further studies are required to elucidate the possible effects of COVID-19 vaccination on the eye.

show abstract

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Cited by 59 publications

References 127 publications

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Reactivation of juvenile idiopathic arthritis associated uveitis with posterior segment manifestations following anti-SARS-CoV-2 vaccination

Vision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019

Contact Info

Product

Resources

About